BCLSI
NRIX icon

Bain Capital Life Sciences Investors’s Nurix Therapeutics NRIX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,132,397
Closed -$16.6M – 27
2024
Q1 		$16.6M Sell
1,132,397
-690,486
-38% -$7.43M 1.34% 16
2023
Q4 		$18.8M Hold
1,822,883
– – 1.8% 15
2023
Q3 		$14.3M Hold
1,822,883
– – 1.6% 15
2023
Q2 		$18.2M Hold
1,822,883
– – 1.88% 18
2023
Q1 		$16.2M Hold
1,822,883
– – 2.02% 17
2022
Q4 		$20M Hold
1,822,883
– – 2.24% 15
2022
Q3 		$23.8M Hold
1,822,883
– – 2.84% 13
2022
Q2 		$23.1M Buy
1,822,883
+538,570
+42% +$6.1M 2.71% 12
2022
Q1 		$18M Hold
1,284,313
– – 1.75% 15
2021
Q4 		$37.2M Sell
1,284,313
-1
-0% -$30 2.95% 12
2021
Q3 		$38.5M Hold
1,284,314
– – 2.39% 12
2021
Q2 		$34.1M Hold
1,284,314
– – 2.23% 10
2021
Q1 		$39.9M Hold
1,284,314
– – 2.26% 12
2020
Q4 		$42.2M Hold
1,284,314
– – 2.65% 11
2020
Q3 		$44.8M Buy
+1,284,314
New +$32.4M 4.18% 8

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Bain Capital Life Sciences Investors's NRIX Position: Q2 2024 in Review

Bain Capital Life Sciences Investors sold out of Nurix Therapeutics (NRIX) in Q2 2024, closing a stake of 1,132,397 shares — an estimated $16.6M sold.

Bain Capital Life Sciences Investors first reported a position in NRIX in Q3 2020 and held it in 15 quarters. The position peaked at $44.8M in Q3 2020. 174 funds tracked by Wall St. Rank hold NRIX as of Q2 2024.

  • Bain Capital Life Sciences Investors reported no remaining Nurix Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 1,132,397 Nurix Therapeutics shares in Q2 2024, an estimated $16.6M.
  • Bain Capital Life Sciences Investors first reported a position in Nurix Therapeutics in Q3 2020 and held it in 15 quarters.
  • Bain Capital Life Sciences Investors's Nurix Therapeutics position peaked at $44.8M in Q3 2020.
  • 174 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2024.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2024, filed 12 Aug 2024.